Envoy Medical Closes Upsized Public Offering to Fund Growth

Envoy Medical ( (COCH) ) just unveiled an announcement.

On February 12, 2026, Envoy Medical announced the closing of an upsized public offering of 75 million shares of Class A common stock or pre‑funded warrants, plus Series A‑1 and Series A‑2 common warrants covering up to 120 million additional shares, at a combined price of $0.40 per share and accompanying warrants. The deal, led by Nantahala Capital with participation from healthcare‑dedicated funds and existing shareholder Glen Taylor as well as company insiders, generated approximately $30 million in gross proceeds, with up to $48 million more possible if milestone‑linked warrants tied to FDA submission and approval of the Acclaim cochlear implant are fully exercised for cash.

Envoy Medical said the net proceeds extend its cash runway into the second half of 2027, carrying the company beyond the expected Premarket Approval submission for Acclaim and, if all milestone warrants are exercised, potentially into the second year of commercialization. The financing, for which H.C. Wainwright acted as exclusive placement agent, is intended to fund working capital and general corporate purposes during the FDA pivotal clinical study, and underscores investor confidence in the company’s fully implanted cochlear implant strategy and its ambition to capture and expand a multi‑billion‑dollar hearing market.

The most recent analyst rating on (COCH) stock is a Hold with a $0.58 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.

Spark’s Take on COCH Stock

According to Spark, TipRanks’ AI Analyst, COCH is a Neutral.

The score is primarily constrained by very weak financial performance (minimal/contracting revenue, large losses, negative equity, and sustained cash burn). Technicals also lean bearish with a negative MACD and price below key moving averages. Corporate events provide some support via listing extension and capital-flexibility steps, but are offset by the minimum bid deficiency risk, while valuation is difficult to support due to losses and no dividend.

To see Spark’s full report on COCH stock, click here.

More about Envoy Medical

Envoy Medical Inc. (NASDAQ: COCH) is a hearing health company focused on innovative technologies across the hearing loss spectrum. It has pioneered fully implanted devices, including the Esteem active middle ear implant, commercially available in the U.S. since 2010, and the investigational fully implanted Acclaim cochlear implant aimed at improving access, usability, compliance, and quality of life.

Based in White Bear Lake, Minnesota, the company targets patients with varying degrees of hearing loss and seeks to expand the multi‑billion‑dollar cochlear implant and hearing solutions market. Envoy Medical positions itself as a disruptor to conventional external hearing aids and traditional cochlear implants by emphasizing fully internal, cosmetically invisible systems.

Average Trading Volume: 703,924

Technical Sentiment Signal: Sell

Current Market Cap: $19.09M

For an in-depth examination of COCH stock, go to TipRanks’ Overview page.